Uncategorized
Novel protein targets tissue factor involvement in neovascular AMD
MIAMI — Best corrected visual acuity outcomes were comparable at 6 months for the combination of ICON-1, a novel protein, plus ranibizumab compared with ranibizumab alone in patients with newly diagnosed age-related macular degeneration, according to a study presented here.“For vision outcomes, we see equivalent gains for ranibizumab only vs. combination. We’re not seeing superiority, we’re not seeing better vision gains for the combination, at least with that dose through the time period,” Carl D. Regillo, MD, FACS, said at the Angiogenesis, Exudation, and Degeneration 2017 annual meeting.